Skip to content
value.today
Cumberland Pharmaceuticals Inc. logo

Cumberland Pharmaceuticals Inc.

CPIX
$65 Mmarket cap on Oct 27, 2026+110.4% since Jan 2024
Compare
World rank
#20,341
Revenue
$45 M
For year ending December-2025
Net income
$-3 M
-6.4% margin
SEC filing
Employees
93
As of December 31, 2025
SEC filing

Cumberland Pharmaceuticals Inc. in brief

Cumberland Pharmaceuticals Inc. is a listed company in the Pharmaceutical industry, based in Nashville,, Tennessee, USA. Its market value was $65 M on 27 October 2026, which makes it the 20,341st largest listed company in the world and the 3,742nd largest in the USA on this site. In the year to December 2025 it had sales of $45 M and a net loss of $3 M. It employs about 93 people and A. J. Kazimi is its chief executive. Its largest product and service lines by sales in 2025 were Sancuso (27%), Kristalose (24%) and Vibativ (21%). Its shares trade under the symbol CPIX (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Cumberland Pharmaceuticals Inc.

Cumberland Pharmaceuticals Inc., is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription pharmaceuticals. We are dedicated to our mission of working together to provide unique products that improve the quality of patient care.

Our primary target markets are hospital acute care, gastroenterology and oncology. These medical specialties are characterized by relatively concentrated prescriber bases that we believe can be served effectively by relatively small, targeted sales forces. We promote our approved products through our hospital, field and oncology sales divisions in the United States. We have also established a network of international partners with the needed regulatory and commercial capabilities to register and provide our medicines to patients in their countries.

From the company's annual report filed with the US SEC: read the report

Cumberland Pharmaceuticals Inc. timeline

3 events, 2002–2025
  1. 2002
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2009
  4. 🔔
    · approximate
    Initial public offering on Nasdaq
  5. 2025
  6. 💰
    Record revenue of $45 million
    FY2025, the highest of the 8 years on record.

Events of Cumberland Pharmaceuticals Inc. from SEC EDGAR, the company record and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$32 M$63 M$95 M$126 M2020202120222023202420252026

World rank over time

▼ down 697 places since 2020
2020-01-01: #19691#19,69120202021-01-01: #21102#21,10220212022-01-07: #26206#26,20620222022-12-25: #27531#27,53120222023-07-30: #28981#28,98120232024-01-05: #27154#27,15420242026-03-08: #10910#10,91020262026-08-01: #16929#16,92920262026-10-09: #18662#18,66220262026-10-27: #20388#20,3882026

Rank in USA: #3,828 (Jan 2020) · #4,126 (Jan 2021) · #4,763 (Jan 2022) · #5,066 (Dec 2022) · #5,150 (Jul 2023) · #4,253 (Jan 2024) · #2,130 (Mar 2026) · #3,356 (Aug 2026) · #3,473 (Oct 2026) · #3,746 (Oct 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
1.6×
Price / book
2.6×
Free cash flow yield
7.4%
Net margin (TTM)
-27.4%
Operating margin
-6.3%
Return on equity
-43.9%
Liabilities / assets
68.1%
Revenue growth
+17.6%
R&D / revenue
12.5%
Revenue per employee
$479 K
Profit per employee
$-31 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $29M, net income $-7M$29MFY18Fiscal year ending Dec 2019: revenue $34M, net income $-4M$34MFY19Fiscal year ending Dec 2020: revenue $37M, net income $-3M$37MFY20Fiscal year ending Dec 2021: revenue $36M, net income $-4M$36MFY21Fiscal year ending Dec 2022: revenue $42M, net income $-6M$42MFY22Fiscal year ending Dec 2023: revenue $40M, net income $-6M$40MFY23Fiscal year ending Dec 2024: revenue $38M, net income $-6M$38MFY24Fiscal year ending Dec 2025: revenue $45M, net income $-3M$45MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$45M+17.6%$-3M$-3M-6.4%
Dec 2024$38M-4.2%$-6M$-6M-17.1%
Dec 2023$40M-5.9%$-10M$-6M-15.9%
Dec 2022$42M+16.7%$-6M$-6M-13.3%
Dec 2021$36M-3.9%$-8M$-4M-9.8%
Dec 2020$37M+8.9%$-6M$-3M-8.9%
Dec 2019$34M+17.2%$-9M$-4M-10.3%
Dec 2018$29M—$-11M$-7M-23.7%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$5M$0M$5M$-0.19—
Dec 2024$-1M$0M$-1M$-0.46—
Dec 2023$6M$0M$6M$-0.44—
Dec 2022$8M$0M$8M$-0.38—
Dec 2021$6M$0M$6M$-0.24—
Dec 2020$5M$0M$5M$-0.22—
Dec 2019$3M$0M$3M$-0.23—
Dec 2018$3M$0M$3M$-0.45—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$40M
Net income, trailing 12 months
$-11M
RevenueNet income
Three months to Dec 2024: revenue $10M, net income $-2M$10MDec ’24Three months to Mar 2025: revenue $12M, net income $1M$12MMar ’25Three months to Jun 2025: revenue $11M, net income $-1M$11MJun ’25Three months to Sep 2025: revenue $8M, net income $-2M$8MSep ’25Three months to Dec 2025: revenue $14M, net income $-1M$14MDec ’25Three months to Mar 2026: revenue $9M, net income $-3M$9MMar ’26Three months to Jun 2026: revenue $9M, net income $-4M$9MJun ’26Three months to Sep 2026: revenue $2M, net income $78M$2MSep ’26

Latest quarter to Sep 2026: revenue $2M (-73.9% on a year earlier), net income $78M. Trailing 12 months to Jun 2026.

SEC filings

Official filings of Cumberland Pharmaceuticals Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$45 M
Operating income
$-3 M
Net income
$-3 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$77 M
Total liabilities
$52 M
Total equity
$25 M

As of December-2025

Top 35 institutional investors in Cumberland Pharmaceuticals Inc.#

As of Sep 30, 2026
35 institutions held 3.2 M shares (about 21.2% of the shares outstanding) on Sep 30, 2026. The ten largest hold 17.7%. Source: SEC Form 13F filings, filed through Nov 16, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Cumberland Pharmaceuticals Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Diversified Trust Co700,000New4.67%$5 MNov 6, 2026
2Ikarian Capital, LLC503,1530 (0.00%)3.36%$4 MNov 16, 2026
3Renaissance Technologies LLC426,463-51,800 (-10.83%)2.85%$3 MNov 12, 2026
4Vanguard Capital Management LLC379,4780 (0.00%)2.53%$3 MNov 13, 2026
5Dimensional Fund Advisors LP184,014-49,291 (-21.13%)1.23%$1 MNov 4, 2026
6Boothbay Fund Management, LLC112,5440 (0.00%)0.75%$1 MNov 16, 2026
7Geode Capital Management, LLC108,820+407 (+0.38%)0.73%$1 MNov 6, 2026
8Informed Momentum Co LLC94,948New0.63%$1 MNov 16, 2026
9Jane Street Group, LLC80,592+23,851 (+42.03%)0.54%$1 MNov 12, 2026
10Citadel Advisors LLC62,817-10,574 (-14.41%)0.42%$0 MNov 16, 2026
11BlackRock, Inc.62,217-1,330 (-2.09%)0.42%$0 MNov 13, 2026
12Bank of New York Mellon Corp58,4580 (0.00%)0.39%$0 MNov 5, 2026
13SEI Investments Co57,308New0.38%$0 MNov 10, 2026
14Vanguard Fiduciary Trust Co54,9090 (0.00%)0.37%$0 MNov 13, 2026
15State Street Corp40,928+1,418 (+3.59%)0.27%$0 MNov 12, 2026
16Bridgeway Capital Management, LLC25,789-411 (-1.57%)0.17%$0 MNov 16, 2026
17UBS Group AG25,062-1,277 (-4.85%)0.17%$0 MNov 10, 2026
18Northern Trust Corp24,739+2,786 (+12.69%)0.17%$0 MNov 16, 2026
19Bailard, Inc.24,6240 (0.00%)0.16%$0 MOct 13, 2026
20Empowered Funds, LLC24,589New0.16%$0 MNov 13, 2026
21Arrowstreet Capital, Limited Partnership23,822+3,570 (+17.63%)0.16%$0 MNov 13, 2026
22HRT Financial LP23,325New0.16%$0 MNov 13, 2026
23Magnolia Capital Advisors LLC20,000New0.13%$0 MNov 16, 2026
24Prudential Financial Inc19,633New0.13%$0 MNov 16, 2026
25Cresset Asset Management, LLC18,475-1,000 (-5.13%)0.12%$0 MNov 16, 2026
Show all 35: investors 26 to 35
Institutional investors 26 to 35 in Cumberland Pharmaceuticals Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Lantern Wealth Advisors, LLC13,500New0.09%$0 MOct 22, 2026
27Vanguard Global Advisers, LLC4,500New0.03%$0 MNov 13, 2026
28Morgan Stanley3,410+149 (+4.57%)0.02%$0 MNov 13, 2026
29Tower Research Capital LLC (TRC)769+578 (+302.62%)0.01%$0 MNov 16, 2026
30Capital Advisors, Ltd. LLC4370 (0.00%)0.00%$0 MOct 27, 2026
31Royal Bank Of Canada416New0.00%$0 MNov 16, 2026
32Barclays PLC395+347 (+722.92%)0.00%$0 MNov 6, 2026
33Osaic Holdings, Inc.240+40 (+20.00%)0.00%$0 MNov 12, 2026
34Wells Fargo & Company/mn1000 (0.00%)0.00%$0 MNov 16, 2026
35FMR LLC41+20 (+95.24%)0.00%$0 MNov 10, 2026

Mutual funds holding Cumberland Pharmaceuticals Inc.#

29 funds hold shares worth $5 M (about 4.9% of the company). Since their previous reports 7 added shares and 3 sold, selling $0 M net.
Mutual funds holding Cumberland Pharmaceuticals Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.274,814$2 M1.8%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.99,719$1 M0.67%<0.01%+15%Jun 30, 2026
🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP49,950$0 M0.33%<0.01%no changeJul 31, 2026
🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP47,772$0 M0.32%<0.01%no changeJul 31, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC47,968$0 M0.32%<0.01%+0.3%May 31, 2026
🇺🇸 U.S. Targeted Value PortfolioDimensional Fund Advisors LP37,593$0 M0.25%<0.01%−42%Jul 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors28,898$0 M0.19%0.01%+26%Jun 30, 2026
🇺🇸 Nationwide Bailard Small Cap Value FundNATIONWIDE FUND ADVISORS24,624$0 M0.16%0.13%no changeJul 31, 2026
🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC25,000$0 M0.17%0.11%no changeJun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC17,887$0 M0.12%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC13,522$0 M0.09%<0.01%+9.1%May 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC11,327$0 M0.08%<0.01%no changeMay 31, 2026
🇺🇸 Dimensional U.S. Targeted Value ETFDimensional Fund Advisors LP6,441$0 M0.04%<0.01%−83%Jul 31, 2026
🇺🇸 U.S. Small Cap PortfolioDimensional Fund Advisors LP6,355$0 M0.04%<0.01%no changeJul 31, 2026
🇺🇸 U.S. Core Equity 2 PortfolioDimensional Fund Advisors LP4,933$0 M0.03%<0.01%no changeJul 31, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.4,945$0 M0.03%<0.01%newJun 30, 2026
🇺🇸 U.S. Sustainability Core 1 PortfolioDimensional Fund Advisors LP4,562$0 M0.03%<0.01%no changeJul 31, 2026
🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP3,702$0 M0.02%<0.01%no changeJul 31, 2026
🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust3,758$0 M0.03%<0.01%no changeMay 31, 2026
🇺🇸 Dimensional US Sustainability Core 1 ETFDimensional Fund Advisors LP2,780$0 M0.02%<0.01%no changeJul 31, 2026
🇺🇸 JNL/DFA U.S. Small Cap FundJackson National Asset Management, LLC2,800$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 U.S. Vector Equity PortfolioDimensional Fund Advisors LP2,517$0 M0.02%<0.01%no changeJul 31, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC1,991$0 M0.01%<0.01%+34%Jun 30, 2026
🇺🇸 AZL DFA U.S. Core Equity FundAllianz Investment Management LLC1,468$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Small Cap Opportunities TrustJohn Hancock Variable Trust Advisers LLC956$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 JNL/DFA U.S. Core Equity FundJackson National Asset Management, LLC900$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Dimensional VA U.S. Targeted Value PortfolioDimensional Fund Advisors LP700$0 M<0.01%<0.01%−84%Jul 31, 2026
🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC363$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 U.S. Social Core Equity 2 PortfolioDimensional Fund Advisors LP331$0 M<0.01%<0.01%no changeJul 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 29 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Cumberland Pharmaceuticals Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
22
since
$12 K$0Oct 2024: bought $12 K (92 trades), sold $0 (0 trades)Oct 24Nov 2024: bought $12 K (80 trades), sold $0 (0 trades)Dec 2024: bought $10 K (60 trades), sold $0 (0 trades)DecMar 2025: bought $6 K (84 trades), sold $0 (0 trades)Apr 2025: bought $6 K (84 trades), sold $0 (0 trades)AprMay 2025: bought $6 K (84 trades), sold $0 (0 trades)Jun 2025: bought $6 K (80 trades), sold $0 (0 trades)JunJul 2025: bought $8 K (88 trades), sold $0 (0 trades)Aug 2025: bought $6 K (84 trades), sold $0 (0 trades)Aug
Bought (open market)Sold (open market)Hover a month for the totals
Cumberland Pharmaceuticals Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Martin S. Brown Jr.DirectorGrant or award+1,800$2.800$5 K10,300Form 4
filed Kenneth KrogulskiDirectorGrant or award+1,800$2.800$5 K298,338Form 4
filed Caroline YoungDirectorGrant or award+1,800$2.800$5 K35,109Form 4
filed Joseph C. GalanteDirectorGrant or award+1,800$2.800$5 K63,656Form 4
filed James JonesDirectorGrant or award+1,800$2.800$5 K46,863Form 4
filed Kenneth KrogulskiDirectorGrant or award+4,000$2.800$11 K302,338Form 4
filed A. J. KazimiChairman and CEO, Director, 10% ownerShares withheld for tax-5,845$3.060$18 K5.70 MForm 4
filed James JonesDirectorSmall acquisition10b5-1 plan+7$3.910$2745,063Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Cumberland Pharmaceuticals Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
300,312
2.0% of shares · 1.75 days to cover
Buybacks, Q3 2026
$0.3M
Q3 2026
Shares sold short, last 24 reportsAll stocks →
Cumberland Pharmaceuticals Inc. share buybacks by quarter
Buybacks, quarterFiscalSpent
Q3 2026Q3 2026$0.3M
Q2 2026Q2 2026$0M
Q1 2026Q1 2025$0.1M
Q4 2025Q4 2025$0M
Q3 2025Q3 2025$0M
Q2 2025Q2 2025$0M
Q1 2025Q1 2025$0.2M
Q4 2024Q4 2024$0.1M
Q3 2024Q3 2024$0.1M
Q2 2024Q2 2024$0.1M
Q1 2024Q1 2024$0.2M
Q4 2023Q4 2023$0.2M
Q3 2023Q3 2023$0.2M
Q2 2023Q2 2023$0.2M
Q1 2023Q1 2023$0.2M
Q4 2022Q4 2022$0.2M

Trading halts

  • 2026-04-23 13:33 UTC, code LUDP, resumed 13:38 UTC
  • 2025-08-06 13:30 UTC, code LUDP, resumed 13:35 UTC
  • 2025-02-05 15:08 UTC, code LUDP, resumed 15:13 UTC
  • 2025-02-05 14:55 UTC, code LUDP, resumed 15:00 UTC

Fails to deliver

  • : 736 shares at $4.35
  • : 198 shares at $7.96
  • : 40,330 shares at $7.18
  • : 668 shares at $7.54
  • : 689 shares at $7.49

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Cumberland Pharmaceuticals Inc. scorecard#

Passes 8 of the 24 checks that could be worked out: strongest in valuation (3 of 6), weakest in profitability (1 of 5). Fiscal year 2025; market cap of Oct 27, 2026.

  • Valuation3 of 6
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median2.6×Price to book 2.6× against Pharmaceutical's median of 3.2×.
    • ✓Price to sales below its peers' median1.6×Price to sales 1.6× against Pharmaceutical's median of 3.5×.
    • ✓Free cash flow yield above 5%7.4%Free cash flow is 7.4% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • ✗The price assumes slower growth than the last three years'7.8%The price assumes 7.8% a year for ten years; revenue grew 1.9% a year over the last three.
  • Growth2 of 6
    • ✓Revenue grew in the newest year17.6%Revenue up 17.6% in fiscal 2025.
    • ✗Revenue up more than 5% a year over three years1.9%1.9% a year over the three years to fiscal 2025.
    • ✗Faster growth over three years than its peers' median1.9%1.9% a year against Pharmaceutical's median of 2.5% (65 companies).
    • ✗Earnings per share grew in the newest year-0.19 vs -0.46Diluted EPS -0.19 in fiscal 2025 against -0.46 the year before (report's currency).
    • ✓Net income higher than five years earlier-$3 M-$3 M in fiscal 2025 against -$3 M in 2020.
    • ✗Revenue rose in at least four of the last five years2 of 5Revenue rose in 2 of the five years to fiscal 2025.
  • Profitability1 of 5
    • ✗Profitable in the newest year-$3 MNet income -$3 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • ✗Operating margin above its peers' median-6.3%-6.3% against Pharmaceutical's median of 1.8% (74 companies).
    • ✗Return on equity above 15%-11.9%-11.9% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✓Operating margin wider than three years earlier-6.3%-6.3% in fiscal 2025 against -13.6% in 2022.
  • Financial health1 of 4
    • ✓Short-term assets cover short-term liabilities1.0×Current ratio 1.01 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • ✗Operating income covers interest five times-5.6×Operating income -5.6 times interest in fiscal 2025.
    • ✗Cash from operations positive in each of the last three years2 of 3Positive in 2 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone0.72Z-score 0.72 (distress zone) for fiscal 2025.
  • Shareholder returns1 of 3
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year5.7%Diluted shares up 5.7% in fiscal 2025.
    • ✗Dividends and buybacks above 3% of the market value0.4%Dividends and buybacks were 0.4% of the market value.
    • ✓Free cash flow covers dividends and buybacks$5 MFree cash flow $5 M against $0 M paid out in fiscal 2025.

Worked out from the statements as filed (sec), the medians of Pharmaceutical, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Cumberland Pharmaceuticals Inc.'s statements, beside the median of Pharmaceutical.

Cumberland Pharmaceuticals Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-6.3%1.8%
Net margin-6.4%-1.5%
Return on equity-11.9%-0.9%
Revenue growth, 3 years a year2.0%2.5%
Revenue growth17.6%7.3%
Free cash flow margin10.9%6.0%

5of 8on the Piotroski tests of financial strength

  • Net loss of $3 million, the 10th loss-making year in a row.
  • The share count rose 5.7% in the year.
  • Operating income covers the interest bill only -5.6 times.
  • Receivables grew 45% while revenue grew 18%: customers are paying later, or sales were booked ahead of cash.

Cumberland Pharmaceuticals Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Cumberland Pharmaceuticals Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue45384042363734r29r4133
Cost of revenue6.76.66.19.18.88.77.4r6.0r7.46.0
Research and development5.64.85.86.75.75.86.9r7.6r4.3r3.2
Selling and marketing19171817151515r14r2115
General and administrative121111109.81010.0r10r9.7r8.6
Total costs and expenses47444948444444r41r4534
Operating income−2.8−6.4−9.6−5.7−7.7−6.4−9.3r−11r−4.1−1.4
Interest and finance income0.50.30.30.10.00.10.20.60.30.2
Interest expense and finance costs0.50.60.70.60.10.30.20.20.10.1
Share of profit of associates−0.00————————
Income before tax−2.8−6.5−6.3−5.6−5.6−6.6−9.3r−11r−3.9−1.3
Income tax0.0−0.00.00.10.00.1−0.10.04.2−0.3
Income from discontinued operations———02.03.25.73.8——
Net income including minority interests−2.9−6.4−6.3−5.7−3.6−3.4−3.5−7.0−8.0−1.0
Minority interests' share of net income−0.00.0−0.1−0.1−0.1−0.1−0.0−0.1−0.1−0.1
Net income attributable to shareholders−2.8−6.5−6.3−5.6−3.5−3.3−3.5−7.0−8.0−0.9
Earnings per share, basic-0.19-0.46-0.44-0.38-0.24-0.22-0.23-0.45-0.50-0.06
Earnings per share, diluted-0.19-0.46-0.44-0.38-0.24-0.22-0.23-0.45-0.50-0.06
Shares, weighted average (basic)15141415151515161616
Shares, weighted average (diluted)15141415151515161616
Balance sheet
Cash and cash equivalents11181820272528284535
Short-term investments——————08.34.716
Receivables17129.8136.9127.9r7.88.47.3
Inventory0.0r4.04.69.98.4118.9r126.75.4
Other current assets0.7r2.83.03.13.32.22.83.03.52.7
Current assets37363646465050596966
Property, plant and equipment0.30.30.40.30.40.60.70.80.50.5
Right-of-use (leased) assets5.8r6.26.75.21.02.03.0———
Goodwill0.90.90.90.90.90.90.90.80—
Other intangible assets0.1r182331242831342122
Total assets7776829384961051139393
Accounts payable191414119.61310.0r119.08.0
Debt due within a year05.10———————
Current liabilities37322829192624281815
Lease liabilities (non-current)4.54.95.34.60.11.12.1———
Total liabilities52535357425053572920
Retained earnings−27−24−17−11−5.6−2.11.24.71219
Shareholders' equity25233036434751566473
Minority interests−0.3−0.3−0.3−0.3−0.2−0.1−0.0−0.3−0.2−0.1
Total equity25232936434751566473
Total liabilities and equity7776829384961051139393
Shares outstanding15141414r151515r15r16r16
Cash-flow statement
Depreciation and amortization4.14.94.95.34.64.74.43.02.62.4
Share-based compensation0.40.30.40.40.71.01.51.41.10.9
Cash from operating activities4.9−0.66.18.56.35.43.13.1−0.60.6
Capital expenditure−0.1−0.1−0.3−0.1−0.1−0.1−0.2−0.5−0.3−0.1
Intangible assets bought−0.1−0.1−0.2−2.0−0.3−2.0−0.8−3.8−1.2−2.0
Cash from investing activities−4.70.1−0.1−14−0.5−1.82.3−289.5−3.1
Shares issued4.7—————————
Shares bought back−0.3−0.6−0.7−1.1−1.4−1.9−3.5−2.9−3.7−2.5
Cash from financing activities−6.70.2−7.4−2.1−3.6−7.1−5.17.11.9−1.1
Change in cash−6.5−0.4−1.4−7.32.3−3.50.3−1711−3.7
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Cumberland Pharmaceuticals Inc. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • Product(total)$40 M91%
  • Sancuso$12 M27%
  • Kristalose$11 M24%
  • Vibativ$9 M21%
  • Caldolor$5 M10%
  • Product - Other$4 M9.3%
  • Other$4 M9.3%
  • Product - Talicia$3 M7.4%
  • Acetadote$1 M1.1%
  • RediTrex$0 M0.0%

Countries and regions

  • Non-US(total)$5 M11%

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Executive pay at Cumberland Pharmaceuticals Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$2.2 M
A. J. Kazimi
Other top executives, average
$341 K
the CEO earned 6.6× this
$100 invested is now
$135
peer group: $132
Cumberland Pharmaceuticals Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025A. J. Kazimi$2.2 M$980 K$341 K$135 (peers $132)
2024A. J. Kazimi$1.1 M$979 K$316 K$46 (peers $62)
2023A. J. Kazimi$980 K$953 K$327 K$35 (peers $43)
2022A. J. Kazimi$583 K$897 K$306 K$44 (peers $49)
2021A. J. Kazimi$1.5 M$873 K$412 K$91 (peers $72)

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Cumberland Pharmaceuticals Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Acquisition or sale completed 1 · Directors and officers 1 · Material agreement 3 · Agreement ended 1 · New debt 1 · Shareholder vote 4 · Results announced 9

Cumberland Pharmaceuticals Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Shareholder vote8-K/A
Results announced8-K
Acquisition or sale completedDirectors and officersMaterial agreementAgreement ended8-K
Shareholder vote8-K
Results announced8-K
Shareholder vote8-K
Material agreement8-K
Results announced8-K
Material agreementNew debt8-K
Results announced8-K
Results announced8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026

Acquisitions and funding#

2 acquisitions, $34 M paid where reported

Businesses it acquired

Acquisitions by Cumberland Pharmaceuticals Inc.
AcquiredAcquisition dateCompletionPriceStakeSource
U.S. Product Asset Rights - Sancuso2022—$14 M—Annual report
Product Assets And Global Rights - Vibativ2018—$20 M—Annual report

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Lobbying by Cumberland Pharmaceuticals Inc.#

$0 spent on lobbying the US Congress and federal agencies in 2021.

Lobbying, 2021
$0
#1,447 among companies on value.today
Own lobbyists
No
only outside firms
Firms hired
1
in 2021
2026 so far
—

Lobbying firms hired in 2021

JEFFREY J. KIMBELL AND ASSOCIATES

Cumberland Pharmaceuticals Inc.: lobbying spending by year
YearSpendingOwn lobbyistsReports
2021$0—1
2020$20 K—1

Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Cumberland Pharmaceuticals”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero

FDA drug approvals: Cumberland Pharmaceuticals Inc.#

1 approved applications held; 1 approvals and 0 new uses in 2007.

Approvals held
1
New molecular entities
0
New uses approved
0
efficacy supplements
Generics
0
1 new drugs, 0 biologics
Cumberland Pharmaceuticals Inc.: latest FDA approvals
ApprovedDrugKind
2007-02-28VaprisolConivaptan Hydrochloride · NDA022016New drug (NDA)

Source: Drugs@FDA (openFDA). Approvals are listed under the application's current holder (CUMBERLAND PHARMS), so they follow acquisitions

Layoffs at Cumberland Pharmaceuticals Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
0
2012–2012
Latest
—
2012-11-29
Cumberland Pharmaceuticals Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2012············—
Cumberland Pharmaceuticals Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
Not statedRestructuring planSEC 8-KCompany-wide planFiling

Source: State WARN notices and SEC 8-K item 2.05

How Cumberland Pharmaceuticals Inc. compares in Pharmaceutical

  • Market cap$65 M · higher than 14% of 393
  • Revenue$45 M · higher than 14% of 324
  • Net margin-27.4% · higher than 12% of 313
  • Revenue growth17.6% · higher than 73% of 107
  • Price / sales1.6× · lower than 66% of 219
  • Price / book2.6× · lower than 44% of 207
  • FCF yield7.4% · higher than 75% of 69

Peer comparison · Pharmaceutical

CompanyMarket capP/ENet marginRev. growth
Cumberland Pharmaceuticals Inc.🇺🇸$65 M—-27.4%+17.6%
Eli Lilly and Company🇺🇸$1.20 T43.4×31.9%+44.7%
Johnson & Johnson🇺🇸$652.5 B40.5×16.2%+6.0%
AbbVie Inc.🇺🇸$514.0 B49.7×15.7%+8.6%
Roche Holding AG🇨🇭$370.3 B29.1×19.0%—
Merck & Co., Inc.🇺🇸$359.8 B146.7×3.6%+1.3%
Novartis AG🇨🇭$286.8 B20.5×24.7%—
Amgen Inc.🇺🇸$249.2 B26.5×24.1%+9.9%
AstraZeneca PLC🇬🇧$242.6 B23.7×17.4%+8.6%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 27, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of December 31, 2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Cumberland Pharmaceuticals Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Cumberland Pharmaceuticals Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Cumberland Pharmaceuticals Inc.? Suggest a correction